T-cells genetically engineered to target an antigen associated with human breast cancer dramatically extended survival when used as an adjuvant therapy in mice Australian researchers report.


In fact mice treated with the engineered T-cells lived significantly longer than those given doxorubicin 5-fluorouracil or herceptin as adjuvant therapy Dr. Philip K. Darcy of the Peter MacCallum Cancer Institute in East Melbourne and colleagues report in the August issue of The Journal of Immunology

http://www.medscape.com/viewarticle/488569